로딩 중…
지수 로딩 중…
KANGSTEM BIOTECH CO., LTD.
217730· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,933+3.26%
2026-11-02
Financials
Valuation Metrics
KANGSTEM BIOTECH CO., LTD.'s Market Cap is ₩1818B. At end of 2025 it was ₩2182B. Ranked #859 of 2,410 in KR market (top 36%), #393 of 1,631 on KOSDAQ (top 24%), #96 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 181.81B KRW | KR#859/2,410 Sec#96/231 |
| Revenue | 3.03B KRW | KR#2,361/2,410 Sec#206/231 |
| Net Income | -11.56B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 68.42B KRW | KR#2,022/2,410 Sec#167/231 |
| Net Assets | 56.56B KRW | KR#1,820/2,410 Sec#152/231 |
| Employees | 95 | KR#1,674/2,410 Sec#133/231 |
| Value | ||
| P/B | 3.21x | KR#2,157/2,410 Sec#173/231 |
| P/S | 59.91x | KR#2,368/2,410 Sec#200/231 |
| FCF Yield | -6.79% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -20.43% | KR#2,092/2,410 Sec#164/231 |
| ROA | -16.89% | KR#2,204/2,410 Sec#169/231 |
| Op. Margin | -630.05% | KR#2,361/2,410 Sec#208/231 |
| Revenue Growth | -33.14% | KR#2,225/2,410 Sec#198/231 |
| Financial Health | ||
| Debt Ratio | 20.98% | KR#386/2,410 Sec#48/231 |
| Total Debt | 7.57B KRW | KR#1,700/2,410 Sec#157/231 |
| FCF | -12.34B KRW | KR#1,758/2,410 Sec#157/231 |
| Cash | 911.2M KRW | KR#2,333/2,410 Sec#222/231 |
| Current Ratio | 3.96x | KR#390/2,410 Sec#61/231 |
| Performance | ||
| 1Y Return | 34.05% | KR#238/2,410 Sec#11/231 |
| 1M Return | -13.71% | KR#1,430/2,410 Sec#148/231 |
| From 52W High | -58.78% | KR#1,625/2,410 Sec#136/231 |
| 1Y MDD | -60.33% | KR#1,457/2,410 Sec#117/231 |
| Trading | ||
| Volume | 207,554 shares | KR#315/2,410 Sec#30/231 |
| Trading Value | 396.5M KRW | KR#859/2,410 Sec#93/231 |
| Foreign Own. | 2.16% | KR#1,569/2,410 Sec#150/231 |
| Per Share | ||
| EPS | -123 KRW | KR—/2,410 Sec—/231 |
| BPS | 601 KRW | KR#2,364/2,410 Sec#224/231 |
Company Info
동사는 2010년 줄기세포치료제 개발 및 제조를 목적으로 설립되어 2015년 코스닥시장에 상장하였음. 제대혈 유래 줄기세포를 고순도로 분리하고 대량배양하는 원천기술을 보유하고 있으며, 주요 파이프라인으로 퓨어스템-에이디 주(아토피 피부염), 퓨어스템-알에이 주(류마티스 관절염), 오스카(골관절염 치료제)를 개발중임. 줄기세포 배양액 기반 화장품 사업도 영위하며 온라인 유통망을 강화하고 있음. 강스템바이오텍는 2010년에 설립되었으며 서울특별시 강남구에 본사를 두고 있습니다.